This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Prestige Brands Acquires Insight for $750M

Stocks in this article: PBH VRX AGN ZMH

NEW YORK (The Deal) -- Prestige Brands Holdings  (PBH) on Friday joined the pharmaceuticals merger stampede, announcing plans to acquire Trevose, Pa.-based feminine care product manufacturer Insight Pharmaceuticals in a deal valued at $750 million.

Insight sells Monistat brand over-the-counter yeast infection treatments, EPT brand home pregnancy tests and other related products. The company is owned by Swander Pace Capital and co-investment partner Ontario Teachers' Pension Plan, which purchased it from Allied Capital in 2009 for an undisclosed sum.

Tarrytown, N.Y.-based Prestige, a distributor of over-the-counter drugs and household cleaning products, said the Insight deal coupled with another small pending acquisition would create a company with pro forma annual Ebitda of $300 million on about $800 million in sales. Prestige earlier this month said it has a deal to acquire Hydralyte in Australia and New Zealand from the Hydration Pharmaceuticals Trust of Victoria, Australia.

The buyer said as part of the deal it will acquire tax attributes with a present value of about $100 million, lowering the effective purchase price to about $650 million.

Prestige is best known for its Chloraseptic and Luden's brand throat treatments, Clear Eyes eye care products and Beano gas prevention pills. The company also has a line of pediatric products, antacids, dental products and earwax removal tools.

Company CEO Matthew M. Mannelly in a statement said that the purchase will bring it close to its goal of generating $1 billion in annual sales from over-the-counter pharmaceuticals.

"The acquisition of Insight Pharmaceuticals will add the attractive new feminine care platform to the Prestige portfolio," he said. "We expect that our already industry-leading free cash flow and Ebitda margins will further strengthen as a result of the acquisition of Insight."

The deal caps an active week in healthcare M&A. On Monday, Valeant Pharmaceuticals International (VRX) teamed with activist Bill Ackman on a $45 billion hostile bid for Botox maker Allergan (AGN), while Novartis said it would take a host of oncology drugs from GlaxoSmithKline for $16 billion while selling other units to the British drugmaker. Medical device maker Zimmer Holdings (ZMH) on Thursday committed $13.35 billion to acquire Biomet.

Sawaya Segalas served as financial adviser to Prestige Brands on its purchase.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs